Paul Davis, MD
Family Medicine · White Hall, ARNPI 1386637221
Payments from drug & device makers
Across 281 payments — averaging $15.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$498
- Amarin Pharma, Inc.$410
- Bayer$244
- Novo Nordisk$220
- Pfizer$220
- plus $2K from 31 others
What the payments were for
- Speaking & faculty fees$732%
- Food & beverage$4,29497%
- Education$581%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 75 | $1,002 |
| GSK | 31 | $498 |
| Amarin Pharma, Inc. | 27 | $410 |
| Bayer | 16 | $244 |
| Novo Nordisk | 13 | $220 |
| Pfizer | 14 | $220 |
| AstraZeneca(2 entities) | 13 | $209 |
| Novartis | 11 | $186 |
| Lilly USA, LLC | 12 | $180 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $109 |
| Amgen | 6 | $101 |
| Teva Pharmaceuticals USA, Inc. | 5 | $83 |
| Sun Pharmaceutical Industries Inc. | 1 | $73 |
| Supernus Pharmaceuticals, Inc. | 5 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $69 |
| Astellas Pharma US Inc | 4 | $67 |
| Abbott | 3 | $64 |
| Genentech USA, Inc. | 4 | $64 |
| Boehringer Ingelheim | 4 | $60 |
| Shield Therapeutics Inc | 3 | $45 |
| Merck | 2 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Lundbeck LLC | 2 | $38 |
| Biogen | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Sunovion Pharmaceuticals Inc. | 2 | $29 |
| Eisai Inc. | 2 | $25 |
| Alkermes, Inc. | 1 | $25 |
| Antares Pharma, Inc. | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Hologic Sales And Service, LLC | 1 | $17 |
| Angiodynamics, Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Seqirus USA Inc | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $12 |
How this compares
$4,424 in reported general payments places this provider in the 85th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 126 | $137,819 |
| EliquisApixaban | 122 | $77,105 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $64,996 |
| FarxigaDapagliflozin Propanediol | 91 | $61,733 |
| JardianceEmpagliflozin | 52 | $42,779 |
| JanuviaSitagliptin Phosphate | 45 | $33,013 |
| MounjaroTirzepatide | 26 | $32,457 |
| EntrestoSacubitril/Valsartan | 39 | $29,090 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $29,080 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 34 | $28,675 |
| MyrbetriqMirabegron | 30 | $24,406 |
| LinzessLinaclotide | 40 | $22,953 |
| XareltoRivaroxaban | 12 | $21,405 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $20,141 |
| Repatha SureclickEvolocumab | 32 | $19,506 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $220 | $137,819126 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $209 | $105,820174 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $498 | $103,381121 claims |
| PfizerEliquis | $220 | $77,105122 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $60 | $48,77563 claims |
| MerckJanuvia | $45 | $33,01345 claims |
| Lilly USA, LLCMounjaro | $180 | $32,45726 claims |
| NovartisEntresto | $186 | $29,09039 claims |
| Astellas Pharma US IncMyrbetriq | $67 | $24,40630 claims |
| AbbVieLinzess | $1,002 | $22,95340 claims |
| BayerKerendia | $244 | $10,15912 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $29 | $6,50821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in White Hall
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
- Landon HumphreyConway$417K
- Vonda HouchinHarrisburg$206K
- Glenn GibbonsFort Smith$179K
- Christopher BrownJonesboro$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.